Streptokinase, acylated plasminogen streptokinase complex, and tissue-type plasminogen activator (tPA) are widely used for the treatment of acute myocardial infarction. These thrombolytic agents restore blood flow in occluded coronary arteries, salvage myocardial function, and decrease mortality. The success of thrombolytic therapy depends on the prompt and stable recanalization of the occluded blood vessel. Hemorrhagic events undermine the safety of fibrinolytic agents. Most bleeding complications occur at vascular puncture sites and can be avoided by limiting invasive procedures; however, an increased incidence of devastating intracranial bleeds is also encountered. The cause of thrombolytic-induced intracranial hemorrhage is unknown but may be due to lysis of protective hemostatic plugs. Another potential contributor to bleeding is activation of circulating plasminogen by the exogenous plasminogen activator to yield fluid-phase plasmin. Plasmin is a promiscuous proteinase that degrades many proteins that play pivotal roles in hemostasis and the integrity of the microvasculature. Tissue-type plasminogen activator activity is depressed in the absence of fibrin; hence, its use as a thrombolytic agent was anticipated to avoid the untoward consequences of plasminemia. However, the administration of pharmacologic doses of tPA can result in the activation of appreciable quantities of circulating plasminogen. In contrast to currently available thrombolytic agents, the activity of the vampire bat salivary plasminogen activator (BatPA) displays a strict requirement for the presence of fibrin. Assessment of BatPA using animal models of arterial thrombosis has demonstrated efficacy but without activation of systemic plasminogen. The avoidance of plasminemia when using BatPA as a fibrinolytic agent may circumvent bleeding complications that can compromise the safety of thrombolytic therapy.
INTRODUCTION
The critical role of thrombosis in the pathogenesis of acute myocardial infarction (AMI) is now firmly established (12) . A preferred approach for the management of AMI is the administration of thrombolytic agents such as tissue-type plasminogen activator (tPA), streptokinase (SK), or acylated plasminogen streptokinase complex (APSAC). Each of these thrombolytic agents is a plasminogen activator that catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin is a relatively nonspecific proteinase that degrades the fibrin matrix of the occlusive thrombus. Intravenous administration of thrombolytic agents to patients with evolving AMI has been shown to recanalize occluded coronary arteries (8, 46) , salvage ischemic myocardium (33, 47) , and reduce mortality (1, 29, 48) .
CORONARY ARTERY RECANALIZATION
IMPROVES CLINICAL OUTCOME FOLLOWING AMI The early and sustained restoration of blood flow in the occluded coronary vessel is, in principle, the most reasonable strategy for decreasing mortality and morbidity that results from AMI. Clinical trials have demonstrated that mortality reduction was greatest in those patients who were treated early (20, 29) and who exhibited stable reperfusion (35) . Late reperfusion may lead to mortality reduction by preventing infarct extension, reducing the incidence of fatal arrhythmias or ventricular thrombi, improving collateral flow, and increasing the rate of repair and remodeling of the infarction area (40) . Nevertheless, it is difficult to understand how these purported secondary effects can have a profound impact on the overall survival beyond the benefit realized by stable, early reperfusion.
Randomized clinical trials that directly compare tPA and SK have shown that tPA is more efficacious than SK for early coronary artery recanalization (8, 46) . The overall coronary artery patency at 90 min after the start of the infusion was 70 and 46% in the tPA-and SK-treatment groups, respectively. Hence, tPA is more efficient than SK at restoring blood flow in the occluded coronary vessels within a time period that is useful for the salvage of myocardial tissue. Nevertheless, the recent, large comparative clinical trials of tPA and SK (21, 28, 30) have not shown that tPA is superior to SK with respect to mortality reduction. The failure to realize improved survival in the tPA treatment groups of these large mortality trials may result from inadequate conjunctive treatment with heparin (9). Hence, a salutory effect due to the greater rapidity of tPA-mediated reperfusion may be offset in these large trials by a heightened risk of acute reocclusion.
BLEEDING COMPLICATIONS UNDERMINE SUCCESSFUL THROMBOLYTIC THERAPY
The most common complication of thrombolytic therapy is hemorrhage (6) . The bleeding episodes are generally divided into 2 categories: spontaneous and intervention-related. The typical spontaneous bleeding events are intracerebral, gastrointestinal, and retroperitoneal. The intervention-related bleeding complications are encountered at vascular access sites established for pre-and post-thrombolytic invasive procedures (e.g., cardiac catheterization, coronary angioplasty, coronary artery bypass grafting).
The frequency of major bleeding events in patients treated with fibrinolytic agents ranges from more than 30% (when invasive procedures were part of the protocol) to less than 5% (with minimal application of invasive procedures) (14) . Hence, the majority of the hemorrhagic episodes complicating thrombolytic therapy occur at vascular puncture sites and can be avoided by limiting the number of invasive procedures. Intracerebral hemorrhage caused by thrombolytic agents is a dreaded spontaneous bleeding complication that can have devastating consequences. Most studies using currently recommended doses of thrombolytic agents report intracerebral bleeding rates between 0.2 and 0.7°l0 (41) .
POTENTIAL ADVANTAGES OF A FIBRIN-SELEcrrvE THROMBOLYTIC AGENT
Tissue-type plasminogen activator activity is markedly stimulated in the presence of fibrin (7, 27) . Consequently, tPA preferentially activates fibrinbound plasminogen and generally spares fluid-phase plasminogen from activation (Fig. 1 ); this attribute is commonly designated as &dquo;fibrin selectivity.&dquo; In contrast, SK and APSAC indiscriminately catalyze the activation of both fibrin-bound and free plasminogen.
The impressive rapidity of tPA-mediated coronary artery recanalization may arise from tPA's marked fibrin selectivity. Consumption of circulating plasminogen depletes fibrin-bound plasminogen (due to equilibrium between these 2 pools of plasminogen) and curtails the intensity of the fibrinolytic response (44) . In addition, the generation of plasmin in circulation is believed to elicit a procoagulant response, possibly mediated through the enhanced activation of factor Xa (13) . Avoidance of these purported &dquo;anti-fibrinolytic&dquo; effects when using a fibrin-selective thrombolytic agent may thus contribute to the rapid and stable reperfusion of the occluded coronary vessel.
The onset of plasminemia may also undermine the safety of thrombolytic therapy by provoking bleeding complications. The generation of circulating plasmin (at levels in excess of the endogenous a2-antiplasmin) results in the proteolytic degradation of numerous proteins that play pivotal roles in hemostasis including fibrinogen, factor V, factor VIII, and von Willebrand factor. Furthermore, severe plasminemia could compromise vascular integrity as well (39) .
The expectation that a minimal hemorrhagic risk would be realized when using a fibrin-selective thrombolytic agent has generally not been supported by clinical experience with tPA and SK. Although extreme hypofibrinogenemia is associated with bleeding complications (2, 5, 37), the relation between the extent of the lytic state and hemorrhage bleeding has not consistently shown the levels of precision necessary for clinical prediction of the bleeding risk in individual patients (45) . Importantly, the potential safety advantage offered by fibrin selectivity may be masked by concomitant adjunctive measures using anticoagulant (e.g., heparin) and antiplatelet (e.g., aspirin) agents to prevent reocclusion.
The large randomized comparative clinical trials (28, 30) reported a higher incidence of intracranial hemorrhage in tPA-treated patients (0.66%) than in those who received SK (0.24%). Patients who received APSAC (a fibrin-nonselective agent) in the ISIS-3 trial also showed a statistically higher incidence (0.55%) of intracranial bleeds than the SKtreatment group. Hence, the fibrin selectivity oftPA is not necessarily responsible for the apparently higher risk of intracranial bleeds.
The disappointing safety performance oftPA may arise because its plasminogen activator activity is not strictly dependent on the presence of fibrin. Am-FIG. 1.-Molecular events that follow the administration of fibrinolytic agents. The exogenous plasminogen activator will activate fibrin-bound plasminogen and varying amounts of &dquo;free&dquo; plasminogen. The activation of fibrin-bound plasminogen generates fibrin-bound plasmin which then degrades the fibrin matrix of the thrombus to yield fibrin degradation products. The activation of &dquo;free&dquo; plasminogen generates &dquo;free&dquo; plasmin which is initially and rapidly consumed by a2-antiplasmin. After the a2-antiplasmin has been exhausted, the &dquo;free&dquo; plasmin then degrades plasma proteins such as fibrinogen to yield fibrinogen degradation products.
ple clinical experience shows that the use of tPA as a fibrinolytic agent frequently results in the activation of substantial amounts of circulating plasminogen (37, 42) . The in vitro fibrin selectivity of tPA may be undermined in vivo because plasma proteins other than fibrin act as surrogate cofactors (e.g., fibrinogen) (4). In addition, tPA is known to bind to endothelial cells (23, 24) , and this interaction was reported to promote plasminogen activation (24) . The local generation of plasmin could devastate the integrity of the microvasculature and precipitate bleeding complications that would be especially conspicuous when they occur in the intracranial circulation.
Several attempts are underway using tPA mutants (3), chimeric (tPA/urokinase) species (31) , and complexes between monoclonal antibodies and plasminogen activators (22) to develop a thrombolytic agent that displays greater selectivity than native tPA for fibrin-bound plasminogen. Our laboratory has shown that the plasminogen activator present in vampire bat (Desmodus rotundus) saliva (BatPA) represents an important stride forward in the pursuit of this elusive objective. BATPA 
Biochemistry
The structure of BatPA deduced from its complementary DNA sequence (15) is homologous to tPA (36) (Fig. 2 ). The two conspicuous structural differences between BatPA and tPA are (a) BatPA contains a single kringle whereas tPA contains 2 and (b) BatPA is not proteolytically cleaved by plasmin to generate a 2-chain derivative, unlike tPA.
The activity of BatPA can be distinguished from that of tPA by its strict requirement for the presence of fibrin (4, 15, 16, 25) . In the absence of a fibrinogen-related cofactor, BatPA's second-order rate constant (ka,/K~,,) for the activation of plasminogen was 4 M-1 sec-1 (Table I) . The corresponding ~/ K,. exhibited by tPA was 470 M-' sec-1-a value that is approximately 120-fold greater than BatPA. The k~at~Km values displayed by BatPA and tPA in the presence of fibrin II were similar (174,000 and 158,000 M-1 sec-1, respectively). Hence, fibrin II stimulated BatPA and tPA activity by 43,500-and 336-fold, respectively.
In addition to displaying a strict requirement for the presence of fibrin, BatPA was extremely fastidious with respect to the fibrin cofactor that sufficed to stimulate its activity (4). Also shown in Table I are the kca/Km values for plasminogen activation by tPA and BatPA in the presence of a variety of fibrin(ogen)-like cofactors. Fragment X polymer is an early plasmin-mediated degradation product of fibrin II polymer. The data reveal that BatPA was markedly stimulated by polymeric fibrin I or II, moderately stimulated by fragment X polymer, and virtually unaffected by fibrinogen and fibrin I monomer. In contrast, tPA was greatly stimulated by each of these fibrin-related cofactors. (36) . The residues that are identical in both BatPA and tPA are indicated as filled beads. Y, putative carbohydrate attachment site; V, region corresponding to the plasmin sensitive processing site in tPA; * amino acid residues that comprise the catalytic triad. more, BatPA and tPA competed with each other for their respective binding sites on fibrin. We conclude that the disparate fibrin cofactor requirements of BatPA and tPA do not arise from differences in their high-affinity binding interactions with fibrin.
BatPA was slightly less susceptible than tPA to inactivation by plasminogen activator inhibitor type I (PAI-1 ) (16) . The kassoc values for the interaction between PAI-1 and BatPA and tPA (in the presence of fibrinogen) are 4.4 x 106 and 9.5 x 106 M-' sec-', respectively. Animal Studies 1. Efficacy and Fibrin Selectivity. We used animal models of arterial thrombosis to evaluate BatPA's ability to promote thrombolysis. At the same time, we assessed the extent of systemic plasminogen activation that accompanied BatPA treatment. The thrombolytic agents, BatPA and tPA, were administered by bolus or super-accelerated infusions. This dosing strategy is desirable because it shortens the time to initiation of therapy and, hence, may hasten reperfusion. Furthermore, recent clinical trials have suggested that &dquo;front-loaded&dquo; dosing of tPA benefits efficacy as well (43) . In a rabbit model of arterial thrombosis, a thrombus was formed by injecting autologous whole blood, Ca++, and thrombin into an isolated segment of the femoral artery (17) . Following a 60-min aging period, BatPA or tPA was administered by bolus iv infusion, and the restoration of blood flow was monitored with an electromagnetic flow probe. At 14 and 42 nmol/kg, tPA reperfused 15 and 78% of the rabbits, respectively (Table II) . At 4.7, 8.1, 14, and 42 nmol/kg, BatPA reperfused 0, 50, 75, and 80% of the rabbits, respectively. The thrombolytic efficacy of BatPA at 14 nmol/kg was comparable to a 3-fold higher dose of tPA (42 nmol/kg). Although the incidence of reperfusion by BatPA was not significantly different at 42 and 14 nmol/kg, other indices of efficacy such as median time to reperfusion and residual thrombus mass were significantly improved using the 3-fold higher dose.
Analysis of serial blood samples revealed that the administration oftPA (42 nmol/kg) elicited a marked decrease in the levels of plasma fibrinogen-a facile marker for plasminemia ( Fig. 3) . In contrast, the administration of BatPA at 42 nmol/kg did not diminish the levels of circulating fibrinogen. This finding is concordant with the remarkable fibrin selectivity already noted using purified reagents (4, 15) as well as human citrated plasma (16, 25) . BatPA was also compared to tPA using a canine preparation in which an occlusive thrombus was formed by the placement of a copper coil into the femoral artery (34) . The possible advantages of this model over the rabbit model are: (a) thrombi induced with a copper coil are enriched with platelets-a situation reminiscent of arterial thrombi found in patients-and (b) the tendency to reocclude following the initial reperfusion event can be assessed.
The reperfusion incidences after the administration of tPA and BatPA at 14 nmol/kg were 50 and 88%, respectively (Table III) . The mean times to reperfusion were not significantly different in the BatPA and tPA treatment groups. All animals reoccluded during the 4-hr trial; however, the mean time to reocclusion in the dogs treated with BatPA, 144 min, was significantly delayed relative to those treated with tPA, 37 min. The approximate 6-fold longer mean residence time of BatPA (Table IV) , relative to tPA, was a likely contributor to the delayed reocclusion and superior thrombolytic efficacy in the BatPA treat- ment group. The clearance profile for tPA was monoexponential, with a t~,2 of 2.4 min. The clearance profile for BatPA was biexponential, with a t,,z« of 0.9 min and a t,,2(3 of 20.2 min. Interestingly, the steady-state volume of distribution displayed by BatPA was 16-fold greater than that oftPA. Perhaps some BatPA is initially sequestered in an extraplasma compartment following administration and subsequently released slowly back into circulation.
The canine fibrinogen levels were essentially unaffected following the administration of BatPA or tPA. Nevertheless, the absence of fibrinogenolysis in the BatPA treatment group is noteworthy because of BatPA's prolonged mean residence time.
2. Bleeding. The safety profile of BatPA with respect to bleeding complications was investigated using 2 rabbit bleeding models: template incision and cuticle transsection. The template bleeding model is a commonly used assay of primary hemostasis. The administration of BatPA or tPA to aspirin-treated rabbits evoked an increase in the template bleeding time (Fig. 4) (17) . Equimolar amounts of tPA and BatPA appeared to be equipotent with respect to the elevation of the template I k.l.l.li ,, FIG. 3. -Rabbit fibrinogen levels following the administration of BatPA, tPA, or vehicle. Rabbits containing an experimentally-occluded femoral artery received vehicle (A), tPA (42 nmol/kg, 8), or BatPA (42 nmol/kg, m) by bolus iv infusion. Blood samples were withdrawn at the indicated times; plasma was prepared and functional fibrinogen was measured using a standard thrombin clotting assay. * p < 0.01 vs vehicle. bleeding times. The increase in the template bleeding times by BatPA occurred despite the avoidance of overt plasminemia. A previous report (19) claimed that elevations in the template bleeding times were predictive of bleeding complications in some patients during thrombolytic therapy. Nevertheless, the significance of the relation between prolongation of the template bleeding time and hemorrhagic diathesis has been challenged (32, 38) .
The striking depletion of the factor VIII levels after the administration of tPA but not BatPA (data not shown) prompted us to explore the effects of these fibrinolytic agents on bleeding with an animal model used to evaluate cogenital factor VIII deficiency (i.e., hemophilia A). We adapted the canine cuticle bleeding model established by Giles (18) to normal rabbits and evaluated the effects of tPA and BatPA administration on the cuticle bleeding times (Mellott et al., manuscript in preparation). Administration of an efficacious thrombolytic dose of tPA, 42 nmol/kg (see Table II ), resulted in a 5-fold prolongation of the cuticle bleeding times. Administration of equimolar BatPA, which is a supra-efficacious thrombolytic dose, did not alter the cuticle bleeding times. Moreover, the severity of bleeding from surgical sites was more profuse in those rabbits that received tPA as compared to rabbits that received BatPA or vehicle (data not shown). CONCLUSION Thrombolytic therapy is an important advance in the management of AMI. Nevertheless, several shortcomings limit the overall benefit realized when using the currently available fibrinolytic agents: 1. Many AMI patients (approximately 20-30%) do not respond to thrombolytic agents. Each value is the mean ± SEM (n = 5).
2. Acute reocclusion occurs in upwards to 25% of those patients who initially reperfuse. 3 . An intolerably high incidence of mortality is still encountered (approximately 10% in the GISSI-2 and ISIS-3 trials). 4 . The incidence of intracranial hemorrhage in association with thrombolytic therapy in clinical practice can exceed 1% (11) . 5 . For those agents such as tPA that are rapidly cleared, thrombolytic efficacy requires that large doses be administered by prolonged constant iv infusion.
Intracranial hemorrhage and other life-threatening spontaneous bleeds, although they occur relatively infrequently, have a crippling effect on the widespread use of fibrinolytic agents for the treatment of AMI. The typical exclusion criteria that are perceived as indicative of an increased stroke or bleeding risk are numerous and disqualify most patients. In a recent study, only a minority of patients (16%) were eligible for thrombolytic therapy using the exclusion criteria of the large thrombolytic trials (10) . Those patients that were excluded from treatment had a 5-fold higher in-hospital mortality compared to patients who received the thrombolytic agent. Introduction of a fibrinolytic agent that is associated with a minimal bleeding risk would certainly improve overall survival among AMI pa-tients. The major impact of a &dquo;safer&dquo; thrombolytic agent on mortality would probably not be the fewer deaths due to less frequent catastrophic bleeding. Instead, a significant decrease in overall mortality should be realized as the &dquo;safer&dquo; thrombolytic agent is administered more liberally to AMI patients; hence, an increased number of these patients would reap the established benefit of early coronary artery recanalization.
A plasminogen activator, such as BatPA, that exhibited strict fibrin selectivity and relatively slow disposition may circumvent the aforementioned shortcomings. The potential virtues of fibrin selectivity with respect to safety and efficacy were described earlier. On the other hand, a slowly cleared thrombolytic agent should act to thwart reocclusion and be conducive to a bolus dosing regimen. The truly novel feature of BatPA is its remarkable selectivity for fibrin-bound plasminogen. Attempts to augment the fibrin selectivity of currently available thrombolytic agents have been generally unsuccessful. However, efforts to produce &dquo;long-acting&dquo; plasminogen activators have been fruitful. For example, APSAC is a derivative of SK that is cleared slowly from circulation. Several tPA mutants also display prolonged residence times in circulation (26) ; nonetheless, tPA mutants that are cleared more slowly invariably precipitate a more profound lytic state.
The desirability of fibrin selectivity in a thrombolytic agent is a seductive concept that is amply supported by both intuitive and theoretical reasoning. General principles of pharmacologic specificity dictate that the plasmin-mediated systemic effects be avoided if they are not obligatory for efficacy. However, the heightened cost-consciousness within the health care industry demands that the relatively expensive &dquo;fibrin-specific&dquo; thrombolytic agents offer a tangible advantage over the less costly alternatives. The predicted therapeutic value of fibrin selectivity has not been supported by the results of the large comparative trials of tPA and SK. Nevertheless, the designs of these trials have been criticized by some investigators, thus fueling continued uncertainty as to the benefit of fibrin selectivity. Hopefully, ongoing clinical studies such as the Global Utilization of Streptokinase and tPA for Occluded Coronary Arteries (GUSTO) trial will conclusively and definitively clarify the potential advantage of a fibrin-specific thrombolytic agent.
Fibrin specificity is one of the few distinguishing features of the individual plasminogen activators that may be a determinant of a more favorable clinical outcome. It will be a pity if selectivity for fibrinbound plasminogen and avoidance of systemic effects are not shown to be truly advantageous. Current thrombolytic therapy too often fails to achieve the desired therapeutic objective. Improvements in both the efficacy and safety of fibrinolytic agents are imperative in order to further minimize the mortality and morbidity that is associated with AMI and other thrombotic disorders.
